X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vilobelimab
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG. Target enrollment of 18 patients reached across three different dose groups.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
Details:
Two out of the first five patients dosed with IFX-1 achieved complete remission. Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities in 3 dose cohorts.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
